However, since there are not yet statistics in respect to correlation between molecular profiles, acquired therapy resistance, and corresponding clinical outcomes, as based on this new classification, information is rare, we have predominantly concentrated on the molecular profiles, pathways, and clinical outcomes based on the 2016 WHO classification [10], but take into consideration the data with primary GBMs that correspond to the new classified ‘GBM, IDH-wildtype’ (CNS WHO grade 4) tumor entity. The gene discussed is IDH1; the disease is glioblastoma.